Results 21 to 30 of about 11,453 (268)

Comparison of Intracoronary Tirofiban And Intravenous Tirofiban for Major Adverse Cardiac Events and Cerebrovascular Accident

open access: yesPakistan Journal of Health Sciences, 2023
Major Adverse Cardiovascular Events  (MACE) and  and Cerebrovascular Accidents (CVA) have become  primary areas of interest due to the ongoing focal research in cardiovascular  diseases. Objective: To assess the frequency of major adverse cardiac events and cerebrovascular accidents for intracoronary tirofiban and intravenous tirofiban. Methods: It was
Syed Husnain Raza Bukhari   +5 more
openaire   +1 more source

Safety and Efficacy of Low-Dose Tirofiban Combined With Intravenous Thrombolysis and Mechanical Thrombectomy in Acute Ischemic Stroke: A Matched-Control Analysis From a Nationwide Registry

open access: yesFrontiers in Neurology, 2021
Purpose: Tirofiban administration to acute ischemic stroke patients undergoing mechanical thrombectomy with preceding intravenous thrombolysis remains controversial.
Gaoting Ma   +20 more
doaj   +1 more source

Hemorragia alveolar asociada con tirofiban

open access: yesRevista Repertorio de Medicina y Cirugía, 2023
Case: we present a patient with alveolar hemorrhage associated with tirofiban, whose diagnosis was delayed because the initial signs, which were misinterpreted as pneumonia, were unrecognized. Discussion and conclusions: an early and accurate diagnosis is essential to guide the appropriate management of any type of bleeding complication in a patient ...
Alexander Aguilar Arias   +4 more
openaire   +2 more sources

Efficacy and safety of tirofiban in patients with acute ischemic stroke without large-vessel occlusion and not receiving intravenous thrombolysis: A randomized controlled open-label trial

open access: yesJournal of Neurorestoratology, 2022
ObjectiveTo investigate the effectiveness and safety of tirofiban in patients with acute ischemic stroke (AIS) without large-vessel occlusions and not receiving intravenous thrombolysis.MethodsOverall, 267 cases were included in the study (134 cases in ...
Yongpeng Yu   +4 more
doaj   +1 more source

Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation

open access: yesPlatelets, 2022
We aimed to investigate the effects of integrin αIIbβ3 inhibitor tirofiban on hallmarks of platelet activation, degranulation, and aggregation during its use to analyze activated but non-complexed platelets via flow cytometry.
Martina Aguiar Bucsai   +4 more
doaj   +1 more source

Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size [PDF]

open access: yes, 2017
Schattauer GmbH Stuttgart.The emergency management of ST-elevation myocardial infarction (STEMI) involves treatment with dual-antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PPCI). Pain is generally treated with opiates, which
Farag, Mohamed   +5 more
core   +2 more sources

Influence of tirofiban on stroke outcome after mechanical thrombectomy in acute vertebrobasilar artery occlusion

open access: yesBMC Neurology, 2022
Background Even undergoing mechanical thrombectomy (MT), patients with acute vertebrobasilar artery occlusion (AVBAO) still have a high rate of mortality.
Xiding Pan   +6 more
doaj   +1 more source

Abciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopenia [PDF]

open access: yes, 2006
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90080/1/phco.26.3.423 ...
Dorsch, Michael P.   +3 more
core   +1 more source

Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion

open access: yesFrontiers in Pharmacology, 2019
Aim: To assess platelet (PLT) function and bleeding risks in patients with acute coronary syndrome after tirofiban infusion.Methods: Patients diagnosed with acute coronary syndrome from May 2016 to February 2018 in the Department of Cardiac Intensive ...
Xiaoye Li   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy